Document Detail


Heart failure in 2010.
MedLine Citation:
PMID:  20828344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Heart Failure Congress 2010 in Berlin presented the latest trials and trends in the medical and mechanical therapy of heart failure in the presence of impaired or preserved left ventricular ejection fraction. It covered all aspects of heart failure from epidemiology through basic and translational science to prevention. The congress highlighted new drugs, novel biomarkers, updated trials, the role of imaging in risk stratification and the importance of telecare in the reduction of heart failure readmission.
Authors:
Ayman El-Menyar; Wael AlMahmeed
Related Documents :
20350524 - Estimated glomerular filtration rate is an independent predictor for mortality of patie...
19350964 - The severe heart failure questionnaire: italian translation and linguistic validation.
16520254 - Relationships between clinical assessments and patients' perceptions of the effects of ...
15701474 - The impact of chronic heart failure on health-related quality of life data acquired in ...
7585814 - Immunohistochemical evaluation of the developing outflow tract in the rat: achieving ao...
19804104 - Myocardial ischemia and coronary microvascular vasomotion: the impact of hypercholester...
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-10     Completed Date:  2010-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1231-4     Citation Subset:  IM    
Affiliation:
Hamad General Hospital, Cardiology Department, PO Box 3050, Doha, Qatar. elmenyar@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Calcium Channel Blockers / therapeutic use
Cardiac Myosins / physiology
Cardiotonic Agents / therapeutic use
Clinical Trials as Topic
Enzyme Activators / therapeutic use
Guanylate Cyclase / physiology
Heart Failure / diagnosis*,  physiopathology,  therapy*
Humans
Prognosis
Receptors, Vasopressin / antagonists & inhibitors
Risk Assessment
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Cardiotonic Agents; 0/Enzyme Activators; 0/Receptors, Vasopressin; EC 3.6.1.-/Cardiac Myosins; EC 4.6.1.2/Guanylate Cyclase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clopidogrel in acute coronary syndrome: implications of recent study findings.
Next Document:  Pleiotropic effects of statins in atherosclerotic disease.